SMN1 and proximal spinal muscular atrophy: Gene therapy (e.g., onasemnogene abeparvovec for spinal muscular atrophy) used to deliver a functional copy of the SMN1 gene to replace the defective gene in spinal muscular atrophy (SMA) has shown clinical benefits (Ogbonmide et al., 2023).